Carrigent

Exhibitor

Carrigent is a technology-based service provider focusing on the cell and gene therapy industry. We provide contract research and pre-clinical process development services for the optimization of viral vectors and vector production systems to provide vectors that are more efficient and effective. In addition, we are developing technologies for viral vector production, concentrating on three major problems in the space: production costs, gene-of-interest size limitations, and in vivo targeting.
We have made breakthroughs in both the viral backbones and their expression systems, allowing us to provide significant advancements in all three areas. First, we have increased viral titers at least 3-fold over the gold standard, effectively reducing production costs by 60% or more. Second, we are now able to manufacture payloads up to twice the size of what has been the standard, allowing for more sophisticated constructs with better therapeutic potential. Lastly, because of this larger package size we can now add specificity instructions to the vector allowing us to target the payload to the cell, not just to an organ system, significantly reducing dosing requirements. The three of these together make therapies less expensive to manufacture, provide superior efficacy, and limit toxicities.